Silence Therapeutics plc
SLN
$13.55
-$0.14-1.02%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 17.98% | -27.08% | 43.84% | 23.38% | 4.12% |
| Total Depreciation and Amortization | 1.89% | -6.19% | -27.56% | 5.41% | 7.25% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -52.55% | 358.56% | -186.79% | -91.46% | 77.50% |
| Change in Net Operating Assets | 581.17% | 45.75% | -154.00% | 301.31% | -142.91% |
| Cash from Operations | 109.73% | 9.74% | -58.73% | 50.00% | -76.98% |
| Capital Expenditure | -- | -- | 100.00% | 93.75% | -1,100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 549.40% | 118.75% | -203.99% | 3,487.85% | 96.59% |
| Cash from Investing | 549.40% | 118.75% | -204.00% | 3,383.55% | 96.48% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -100.00% | -92.86% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -100.00% | -92.86% |
| Foreign Exchange rate Adjustments | -270.59% | 86.82% | -21.70% | -153.54% | -14.66% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,281.44% | 92.06% | -275.60% | 274.07% | 58.99% |